Testing who benefits from anti–PD-1 immunotherapy in head cancer
Part of Cancer clinical trials.
This study looks for signs in your tumor that can predict how well anti–PD-1 immunotherapy will work for certain head and neck cancers. You may benefit by helping doctors match the right treatment to the right patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your head and neck squamous-cell cancer is back and/or has spread, and can’t be treated with local procedures
- Your tumor can be examined or reached for a biopsy (for example in the mouth, throat, or neck lymph nodes)
- Your care team plans anti–PD-1 immunotherapy for you based on local French treatment guidance
- You can carry out daily activities with limited help (performance status 0–2)
- You have at least one measurable tumor spot that can be tracked on scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at what treatment is best after you first receive chemotherapy plus immunotherapy, then have surgery for head and neck squamous cell cancer. It tries to use how your tumor responds (shown in lab tissue after treatment) to guide the next steps, which may improve outcomes.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a drug called anti-PD-1 (an immunotherapy that helps your immune system attack cancer) for people whose head and neck cancer has returned or spread but can still be removed with surgery. The goal is to see if this treatment helps control the cancer better.
This trial looks for specific signs in your blood and tumor tissue that may show how well immunotherapy is working for recurrent or metastatic head and neck cancer. It aims to help doctors personalize treatment in the future.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.